Here, we explore CD44 function in the context of promoting ovarian cancer therapy resistance, review relevant literature evidence linking CD44 and STAT3 cooperation in tumor progression, and discuss different therapeutic strategies to target CD44 alone or in combination with other molecular targets to improve clinical outcomes in ovarian cancer patients. The gene discussed is STAT3; the disease is ovarian cancer.